Epcoritamab as Consolidation Therapy for High-Risk Pts w/CLL on BTKI

Part of paid clinical trials in Orange, California.

Sponsor
University of California, Irvine
Study ID
NCT07819214
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • BTKi
  • CLL
  • CLL (Chronic Lymphocytic Leukemia)
  • Chronic Lymphocytic Leukemia (CLL)

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This is a phase 2, single-arm, open-label clinical trial determining efficacy of Epcoritamab in subjects with Chronic Lymphocytic Leukemia (CLL) on Burton Tyrosine Kinase Inhibitor (BTKi).

Key Dates

First listed
Sep 14, 2026
Start date
Oct 31, 2026
Status verified
Sep 2026
Primary completion
Oct 31, 2028
Completion
Oct 31, 2032

Study Design

Enrollment
24 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Epcoritamab
    Given IV

Primary Outcome Measure

Rate of Undetectable Measurable Residual Disease (uMRD) at End of Treatment [ Time Frame: 1 year ]

Central Contacts

  • Chao Family Comprehensive Cancer Center University of California, Irvine
    1-877-827-8839
    [email protected]
  • University of California Irvine Medical

Locations (1)

FacilityCityStateZIPSite coordinators
Chao Family Comprehensive Cancer Center, University of California, IrvineOrangeCalifornia92868
Catherine C Coombs, MD
[email protected]
1-877-827-8839

Find similar trials in Orange, CA

Nationwide
Leukemia (other) trialsOncology trialsBlood cancer trials
By condition
Leukemia (other)
By specialty
OncologyBlood cancer
By research site
Chao Family Comprehensive Cancer Center, University of California, Irvine· Orange, CA

Related Studies